6月2日 - ** 库拉肿瘤KURA.O股价在盘前交易中大涨14%至6.49美元
** KURA和日本Kyowa Kirin 4151.T称美国FDA接受了ziftomenib的上市申请 (link)
** 如果获得批准，该药可用于治疗急性髓性白血病（一种血癌）患者。
** 根据美国癌症协会的数据，美国每年约有22000人罹患这种疾病。
** 两家公司表示，Ziftomenib 有可能成为治疗这种侵袭性白血病的首创疗法
** 他们补充说，美国食品药品管理局已批准优先审查，并可能在今年 11 月 30 日前做出决定
** 截至上一交易日收盘，公司股价累计下跌 34.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.